{"prompt": "['MC1575', '75', 'Amendment 2', 'Recommended Hypertension Monitoring and Management for', 'Patients with Catecholamine-Secreting Tumors (BP in mmHg)', '(CTCAE SOC Vascular Disorders/Hypertension)', 'Blood', 'Grade', 'Antihypertensive', 'Pressure', 'Lenvatinib', '(CTCAE v4)', 'Therapy', 'Monitoring', 'Dose Modification', 'Persistent*', 'HOLD lenvatinib until systolic BP', 'BP should be', 'HOLD lenvatinib until', 'Grade 3 Severe', '<159 and diastolic BP 99', 'monitored as', 'systolic BP <159 and', 'Systolic >160', 'recommended', 'diastolic BP 99. After', 'Diastolic >100', 'BP management is identical to', 'by the', 'this, lenvatinib may be re-', 'that for Grade 2 (see steps 1-3', 'treating', 'administered. If BP is still', 'Protocol-specific', 'above) with 2 major exceptions:', 'physician and', 'grade 2, manage as', 'guidance', '1) If systolic BP >180 or', \"patient's\", 'described above for grade', 'supersedes any', 'diastolic BP >110 and the', 'identified', '2 hypertension.', 'other management', 'subject is symptomatic: optimal', 'hypertension', 'guidelines.', 'management is with intensive', 'specialist', 'In most circumstances, if', 'IV support in ICU; STOP', 'unless the', 'BP cannot be controlled', 'lenvatinib and notify hospital', 'subject is', 'after an optimal trial of', 'staff that stopping lenvatinib', 'symptomatic', 'antihypertensive', 'may result in a decrease in BP', 'with', 'medications, consider', 'and', 'systolic BP', 'either 1 dose reduction of', '2) If systolic BP >180 or', '>180 or', 'lenvatinib when systolic', 'diastolic BP>110 and the', 'diastolic BP', 'BP <159 and diastolic BP', 'subject is asymptomatic,', '>110 in', '99 or stopping', \"Consultation with patient's\", 'which case,', 'lenvatinib.', 'identified hypertension', 'monitoring', 'specialist is required as to the', 'should be', 'HOWEVER,', 'proper medical therapy,', 'intensive.', 'If the subject requires', 'addition of additional anti-', 'hospitalization for', 'hypertensive medications and', 'management of', 'monitoring.', 'symptomatic systolic BP', '>180 or diastolic BP', 'NOTE: Stopping or reducing', '>110, permanently', 'the dose of lenvatinib is', 'discontinue lenvatinib or', 'expected to cause a decrease in', 'if BP is controlled to', 'BP. The treating physician', 'systolic BP <159 and', 'should monitor the subject for', 'diastolic BP 99,', 'consider re-starting', 'hypotension and adjust the', 'lenvatinib at 1 lower dose', 'number and dose of', 'level after consultation', 'antihypertensive', 'with the study Principal', 'medication(s) accordingly', 'Investigator', 'Grade 4', 'Optimal management with', 'Intensive', 'Permanently discontinue', 'Life-threatening', 'intensive IV support in ICU;', 'lenvatinib or if systolic', 'consequences of', \"Contact of patient's identified\", 'BP <159 and diastolic BP', 'hypertension', 'hypertension specialist. STOP', '99, consider re-starting', 'lenvatinib and notify hospital', 'lenvatinib at 1 lower dose', 'staff that stopping lenvatinib', 'level after consultation', 'may result in a decrease in BP', 'with the study Principal', 'Investigator', 'Abbreviations: Dihydropyridine calcium-channel blockers (DHP-CCB), selective beta blockers (BB),', 'Angiotensin Converting Enzyme Inhibitors (ACEI), Angiotensin II Receptor Blockers (ARB), alpha beta', 'blocker (ABB)', 'Protocol Version Date:16Aug2018']['MC1575', '76', 'Amendment 2', 'Recommended Hypertension Monitoring and Management for', 'Patients with Catecholamine-Secreting Tumors (BP in mmHg)', '(CTCAE SOC Vascular Disorders/Hypertension)', 'Blood', 'Grade', 'Antihypertensive', 'Pressure', 'Lenvatinib', '(CTCAE v4)', 'Therapy', 'Monitoring', 'Dose Modification', 'See table below for suggested antihypertensive medications by class', 'If subjects require a delay of >2 weeks for management of hypertension, discontinue protocol therapy', '24-48 hours should elapse between modifications of antihypertensive therapy', 'Hypertension should be graded using CTCAE v4', '* NOTE: For the purposes of dosage reductions related to hypertension, persistent', 'hypertension is defined as blood pressure elevations that meet the grading criteria on', 'at least 2 separate measurements 7 days or more apart. (For the purpose of AE', 'grading standard CTCAE will be utilized.)', 'Oral Antihypertensive Medications for patients with secretory tumors', '(Decisions about changes in antihypertensive medications in this group of patients are best', \"made with communication between patient's primary oncologists and identified\", 'hypertension specialist).', 'Agent', 'Initial', 'Intermediate', 'Maximum', 'Hepatic', 'class', 'Agent', 'dose', 'dose', 'dose', 'metabolism', 'Dihydro-', 'nifedipine XL', '30 mg daily', '60 mg daily', '90 mg daily', 'CYP 3A4 substrate', 'pyridine', 'Calcium-', 'amlodipine', '2.5 mg daily', '5 mg daily', '10 mg daily', 'CYP 3A4 substrate', 'Channel', 'Blockers', 'CYP 3A4 substrate', 'felodipine', '2.5 mg daily', '5 mg daily', '10 mg daily', '(DHP CCB)', 'and inhibitor', '12.5 mg 3x', 'captopril', 'daily', '25 mg 3x daily', '50 mg 3x daily', 'CYP 2D6 substrate', 'enalapril', '5 mg daily', '10-20 mg daily', '40 mg daily', 'CYP 3A4 substrate', 'Yes (CYP450', 'ramipril', '2.5 mg daily', '5 mg daily', '10 mg daily', 'Angiotensin', 'unknown)', 'Converting', 'Enzyme', 'lisinopril', '5 mg daily', '10-20 mg daily', '40 mg daily', 'No', 'Inhibitors', 'Yes (CYP450', '(ACEIs)', 'fosinopril', '10 mg daily', '20 mg daily', '40 mg daily', 'unknown)', 'Rarely used:', 'Yes, but not', '4 mg daily', 'none', '8 mg daily', 'perindopril', 'CYP450', 'Rarely used:', '10 mg daily', '20 mg daily', '40 mg daily', 'No', 'quinapril', 'losartan', 'Angiotensin II', '25 mg daily', '50 mg daily', '100 mg daily', 'CYP 3A4 substrate', 'Receptor', 'candesartan', '4 mg daily', '8-16 mg daily', '32 mg daily', 'CYP 2C9 substrate', 'Protocol Version Date:16Aug2018']\n\n###\n\n", "completion": "END"}